Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.

Other analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Moleculin Biotech in a research note on Monday. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

Moleculin Biotech Price Performance

Shares of MBRX stock opened at $1.16 on Wednesday. Moleculin Biotech has a fifty-two week low of $0.40 and a fifty-two week high of $10.35. The stock’s 50-day simple moving average is $1.50 and its 200-day simple moving average is $2.13.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.